A new peer-reviewed Phase 3 trial has directly compared a generic version of semaglutide against the brand-name innovator drug in adults with type 2 diabetes — a development that could have significant implications for drug access and affordability for the millions of people who rely on GLP-1 medications.
What the SIZE-DM Study Set Out to Do
The SIZE-DM study, published in Cardiovascular Diabetology and Endocrinology Reports, enrolled 320 adults in India with type 2 diabetes (T2DM) whose blood sugar was inadequately controlled on metformin alone. The trial was designed as a multicenter, randomized, active-controlled, non-inferiority study — meaning researchers aimed to determine whether the generic formulation performed no worse than the brand-name innovator semaglutide, which is sold as Ozempic for diabetes management.
Semaglutide is a GLP-1 receptor agonist that helps lower blood sugar by stimulating insulin release, suppressing glucagon, and slowing gastric emptying. The injectable brand-name version, Ozempic, is manufactured by Novo Nordisk and has become one of the most widely prescribed diabetes medications in the world.
Why a Generic Semaglutide Trial Matters
For patients and healthcare systems grappling with the high cost of GLP-1 medications, the existence of a rigorously tested generic version is significant. A Phase 3 non-inferiority design is the same standard regulators typically require before approving a new drug — making this level of evidence particularly meaningful for assessing whether a lower-cost alternative could be a viable option.
The study's focus on Indian patients also highlights a growing global push to expand access to effective diabetes therapies in regions where cost barriers are especially acute. India carries one of the largest burdens of type 2 diabetes worldwide.
Key takeaway: The SIZE-DM trial is one of the first Phase 3, head-to-head studies to formally test whether a generic semaglutide injection matches the performance of brand-name Ozempic — a critical step toward potentially broader, more affordable access to this class of medication.
What This Means for Patients Right Now
It is important to note that the full results of the SIZE-DM study, including the specific efficacy and safety outcome data, were not available in the source abstract reviewed for this article. Patients in the United States currently taking Ozempic or Wegovy should be aware that no FDA-approved generic injectable semaglutide exists at this time. Compounded semaglutide — which became available during a period of drug shortage — is a separate and distinct regulatory category from an approved generic.
Patients should not substitute any injectable semaglutide product for their prescribed medication without direct guidance from their prescriber.
What to Watch Next
The full publication of the SIZE-DM study's outcomes data will be worth monitoring. If the generic formulation demonstrated non-inferiority on key measures such as HbA1c reduction and safety profile, it could support regulatory submissions in India and potentially other markets. Longer term, successful generic competition in any major market tends to create pressure on pricing globally. Patients and advocates in the U.S. and Europe will be watching whether similar trials are initiated in their regions.
Frequently Asked Questions
As always, any questions about your current semaglutide prescription — including concerns about cost, availability, or alternative formulations — should be directed to your prescriber or pharmacist, who can provide guidance tailored to your individual health situation.
- Peer-reviewed journal article, 'Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study),' Cardiovasc Diabetol Endocrinol Rep, date not specified in source material.